VYNE Therapeutics Touts Encouraging Pharmacokinetic, Hematology Data From Potential Candidate For Skin Disorder
VYNE Therapeutics Inc (NASDAQ:VYNE) announced first-in-human pharmacokinetic and hematology data from its Phase 1a single and multiple ascending dose trial for…